(en) Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, Vollenweider FX, « Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers », Biol Psychiatry, no pii, , S0006-3223(14)00275-3. (PMID24882567, DOI10.1016/j.biopsych.2014.04.010)modifier
L. Shao et al., Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo, 2021, DOI10.1101/2021.02.17.431629.
(en) Stephen Ross, Anthony Bossis, Jeffrey Guss et Gabrielle Agin-Liebes, « Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial », Journal of Psychopharmacology, vol. 30, no 12, , p. 1165–80. (ISSN0269-8811 et 1461-7285, PMID27909164, PMCIDPMC5367551, DOI10.1177/0269881116675512, lire en ligne, consulté le )
(en) Grob C.S., Danforth A.L., Chopra G.S. et al., « Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer », Arch. Gen. Psychiatry, vol. 68, no 1, , p. 71–8 (PMID20819978, DOI10.1001/archgenpsychiatry.2010.116)
(en) Robin L Carhart-Harris, Leor Roseman, Mark Bolstridge et Lysia Demetriou, « Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms », Scientific Reports, vol. 7, no 1, (ISSN2045-2322, DOI10.1038/s41598-017-13282-7, lire en ligne, consulté le )
Kelley C. O'Donnell, Sarah E. Mennenga, Lindsey T. Owens et Samantha K. Podrebarac, « Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial », Contemporary Clinical Trials, vol. 123, , p. 106976 (ISSN1559-2030, PMID36332827, DOI10.1016/j.cct.2022.106976, lire en ligne, consulté le )
Michael P. Bogenschutz, Stephen Ross, Snehal Bhatt et Tara Baron, « Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial », JAMA psychiatry, vol. 79, no 10, , p. 953–962 (ISSN2168-6238, PMID36001306, PMCID9403854, DOI10.1001/jamapsychiatry.2022.2096, lire en ligne, consulté le ).
(en) Stephen Ross, Anthony Bossis, Jeffrey Guss et Gabrielle Agin-Liebes, « Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial », Journal of Psychopharmacology, vol. 30, no 12, , p. 1165–80. (ISSN0269-8811 et 1461-7285, PMID27909164, PMCIDPMC5367551, DOI10.1177/0269881116675512, lire en ligne, consulté le )
(en) Robin L Carhart-Harris, Leor Roseman, Mark Bolstridge et Lysia Demetriou, « Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms », Scientific Reports, vol. 7, no 1, (ISSN2045-2322, DOI10.1038/s41598-017-13282-7, lire en ligne, consulté le )
Kelley C. O'Donnell, Sarah E. Mennenga, Lindsey T. Owens et Samantha K. Podrebarac, « Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial », Contemporary Clinical Trials, vol. 123, , p. 106976 (ISSN1559-2030, PMID36332827, DOI10.1016/j.cct.2022.106976, lire en ligne, consulté le )
Michael P. Bogenschutz, Stephen Ross, Snehal Bhatt et Tara Baron, « Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial », JAMA psychiatry, vol. 79, no 10, , p. 953–962 (ISSN2168-6238, PMID36001306, PMCID9403854, DOI10.1001/jamapsychiatry.2022.2096, lire en ligne, consulté le ).
(en) Robin L Carhart-Harris, Leor Roseman, Mark Bolstridge et Lysia Demetriou, « Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms », Scientific Reports, vol. 7, no 1, (ISSN2045-2322, DOI10.1038/s41598-017-13282-7, lire en ligne, consulté le )
(en) « FDA approves magic mushrooms depression drug trial », Newsweek, (lire en ligne, consulté le ).
nih.gov
ncbi.nlm.nih.gov
(en) Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, Vollenweider FX, « Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers », Biol Psychiatry, no pii, , S0006-3223(14)00275-3. (PMID24882567, DOI10.1016/j.biopsych.2014.04.010)modifier
(en) Sewell RA, Halpern JH, Pope HG Jr, « Response of cluster headache to psilocybin and LSD », Neurology, vol. 66, no 12, , p. 1920-2. (PMID16801660)modifier
(en) Stephen Ross, Anthony Bossis, Jeffrey Guss et Gabrielle Agin-Liebes, « Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial », Journal of Psychopharmacology, vol. 30, no 12, , p. 1165–80. (ISSN0269-8811 et 1461-7285, PMID27909164, PMCIDPMC5367551, DOI10.1177/0269881116675512, lire en ligne, consulté le )
(en) Grob C.S., Danforth A.L., Chopra G.S. et al., « Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer », Arch. Gen. Psychiatry, vol. 68, no 1, , p. 71–8 (PMID20819978, DOI10.1001/archgenpsychiatry.2010.116)
Kelley C. O'Donnell, Sarah E. Mennenga, Lindsey T. Owens et Samantha K. Podrebarac, « Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial », Contemporary Clinical Trials, vol. 123, , p. 106976 (ISSN1559-2030, PMID36332827, DOI10.1016/j.cct.2022.106976, lire en ligne, consulté le )
Michael P. Bogenschutz, Stephen Ross, Snehal Bhatt et Tara Baron, « Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial », JAMA psychiatry, vol. 79, no 10, , p. 953–962 (ISSN2168-6238, PMID36001306, PMCID9403854, DOI10.1001/jamapsychiatry.2022.2096, lire en ligne, consulté le ).
pubmed.ncbi.nlm.nih.gov
(en) Sandeep M Nayak, « A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression », Psychedelic Med (New Rochelle), (lire en ligne)
Kelley C. O'Donnell, Sarah E. Mennenga, Lindsey T. Owens et Samantha K. Podrebarac, « Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial », Contemporary Clinical Trials, vol. 123, , p. 106976 (ISSN1559-2030, PMID36332827, DOI10.1016/j.cct.2022.106976, lire en ligne, consulté le )
Michael P. Bogenschutz, Stephen Ross, Snehal Bhatt et Tara Baron, « Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial », JAMA psychiatry, vol. 79, no 10, , p. 953–962 (ISSN2168-6238, PMID36001306, PMCID9403854, DOI10.1001/jamapsychiatry.2022.2096, lire en ligne, consulté le ).
(en) Stephen Ross, Anthony Bossis, Jeffrey Guss et Gabrielle Agin-Liebes, « Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial », Journal of Psychopharmacology, vol. 30, no 12, , p. 1165–80. (ISSN0269-8811 et 1461-7285, PMID27909164, PMCIDPMC5367551, DOI10.1177/0269881116675512, lire en ligne, consulté le )
(en) Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, Vollenweider FX, « Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers », Biol Psychiatry, no pii, , S0006-3223(14)00275-3. (PMID24882567, DOI10.1016/j.biopsych.2014.04.010)modifier
(en) Sewell RA, Halpern JH, Pope HG Jr, « Response of cluster headache to psilocybin and LSD », Neurology, vol. 66, no 12, , p. 1920-2. (PMID16801660)modifier
Denis Richard, Jean-Louis Senon et Marc Valleur, Dictionnaire des drogues et des dépendances, Paris, Larousse, coll. « In extenso », , 626 p. (ISBN978-2-03-505431-9, OCLC470123972)